KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Medical Sciences / 2007 / Cilt: 37 - Sayı: 3

Correlations of Serum IL-6 Levels and Prolidase Activity Between Bone Turnover Markers and Bone Mineral Density in Postmenopausal Women With and Without Osteoporosis

Aysun TOKER
Bünyamin BÖREKÇİ
Hülya AKSOY
Asuman ÖZKAN
Sayfa
129–134
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Elevated levels of IL-6 in postmenopausal osteoporosis might have an important role in the pathogenesis of postmenopausal osteoporosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: The purpose of this study was to measure serum prolidase activity and interleukin-2 and 6 (IL-2, IL-6) levels and to investigate the relationship of these parameters with bone mineral density (BMD) and bone turnover markers in postmenopausal women with and without osteoporosis.
📊
Temel Bulgular & Veri:Materials and Methods: 59 postmenopausal women were included in this study (21 women with osteoporosis and 38 without).
💡
Sonuç & Katkı:Elevated levels of IL-6 in postmenopausal osteoporosis might have an important role in the pathogenesis of postmenopausal osteoporosis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Bone turnover · IL-6 · IL-2

Özet

Aim: The purpose of this study was to measure serum prolidase activity and interleukin-2 and 6 (IL-2, IL-6) levels and to investigate the relationship of these parameters with bone mineral density (BMD) and bone turnover markers in postmenopausal women with and without osteoporosis. Materials and Methods: 59 postmenopausal women were included in this study (21 women with osteoporosis and 38 without). Serum IL-2 and IL-6 levels, prolidase activity, osteocalcin (OSC), calcium (Ca), alkaline phosphatase (ALP), urinary deoxypyridinoline (DPD) and BMD were measured in postmenopausal women with and without osteoporosis. Results: Serum prolidase activity was slightly higher in postmenopausal nonosteoporotic women than in postmenopausal osteoporotic women, but the difference did not reach a statistical significance. Mean values of OSC and IL-6 levels were significantly higher in postmenopausal osteoporotic than in nonosteoporotic women (P < 0.05). There were significant correlations between OSC with IL-6 (r = 0.545, p = 0.01) and urinary DPD (r = -0.513, p = 0.01) in postmenopausal osteoporotic women. Conclusions: Serum prolidase activity in postmenopausal osteoporotic women was not correlated with the bone turnover markers and BMD. Elevated levels of IL-6 in postmenopausal osteoporosis might have an important role in the pathogenesis of postmenopausal osteoporosis.

Abstract

Aim: The purpose of this study was to measure serum prolidase activity and interleukin-2 and 6 (IL-2, IL-6) levels and to investigate the relationship of these parameters with bone mineral density (BMD) and bone turnover markers in postmenopausal women with and without osteoporosis. Materials and Methods: 59 postmenopausal women were included in this study (21 women with osteoporosis and 38 without). Serum IL-2 and IL-6 levels, prolidase activity, osteocalcin (OSC), calcium (Ca), alkaline phosphatase (ALP), urinary deoxypyridinoline (DPD) and BMD were measured in postmenopausal women with and without osteoporosis. Results: Serum prolidase activity was slightly higher in postmenopausal nonosteoporotic women than in postmenopausal osteoporotic women, but the difference did not reach a statistical significance. Mean values of OSC and IL-6 levels were significantly higher in postmenopausal osteoporotic than in nonosteoporotic women (P < 0.05). There were significant correlations between OSC with IL-6 (r = 0.545, p = 0.01) and urinary DPD (r = -0.513, p = 0.01) in postmenopausal osteoporotic women. Conclusions: Serum prolidase activity in postmenopausal osteoporotic women was not correlated with the bone turnover markers and BMD. Elevated levels of IL-6 in postmenopausal osteoporosis might have an important role in the pathogenesis of postmenopausal osteoporosis.

🔖

Bu Makaleye Atıf Yap

TOKER, A., BÖREKÇİ, B., AKSOY, H., ÖZKAN, A. (2022). Correlations of Serum IL-6 Levels and Prolidase Activity Between Bone Turnover Markers and Bone Mineral Density in Postmenopausal Women With and Without Osteoporosis. Turkish Journal of Medical Sciences, Cilt: 37 - Sayı: 3, 129–134. https://ajindex.com/articles/611864

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (7)

  1. Myara I, Myara A, Mangeot M, Fabre M, Charpentier C, Lemon- nier A. Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease. Clin Chem 1984; 30: 211- 215. Miltyk W, Annchim T, Wolcyynski S, Pakla J. Estrogen-dependent regulation of prolidase activity in breast cancer MCF-7 cells. Gynecol Endocrinol 1999; 13: 166-174.
  2. Chiu KM, Arnaud CD, Ju J, Mayes D, Bacchetti P, Weitz S et al. Correlation of estradiol, parathyroid hormone, interleukin-6 and soluble interleukin-6 receptor during the normal menstrual cycle. Bone 2000; 26: 79-85.
  3. Chaudhary LR, Spelsbert TC, Rggs BL. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1 beta and tumor necrosis factor alpha: lack of regu- lation by 17-beta estradiol. Endocrinology 1992; 130: 2528- 2534. Rickard D, Russel G, Gowen M. Oestradiol inhibits the release of tumor necrosis factor but not interleukin-6 from adult human osteoblasts in vitro. Osteoporos Int 1992; 2: 94-102.
  4. Rifas L, Kenney JS, Marcelli M, Pacifici R, Cheng SL, Dawson LL et al. Production of interleukin-6 in human osteoblasts and human bone marrow stromal cells: evidence that induction by interleukin- 1 and tumor necrosis factor alpha is not regulated by ovarian steroids. Endocrinology 1995; 136: 4056-4067.
  5. McKane WR, Khosla S, Peterson JM, Egan K, Riggs BL. Circulat- ing levels of cytokines that modulate bone resorption: effects of age and menopause in women. J Bone Miner Res 1994; 9: 1313- 1318. Rachon D, Mysliwska J, Suchecka-Rachon K, Wieckiewicz J, Mys- liwski A. Effect of oestrogen deprivation on interleukin-6 produc- tion by peripheral blood mononuclear cells of postmenopausal women. J Endocrinol 2002; 172: 387-395.
  6. Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in post- menopausal women: a population based study. J Clin Endocrinol Metab 2000; 85: 1340-1344.
  7. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R et al. Serum interleukin-6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001; 86: 2032-2042. Pacifici R. Estrogen, cytokines and pathogenesis of post- menopausal osteoporosis. J Bone Miner Res 1996; 11: 1043- 1051. Gür A, Denli A, Cevik R, Nas K, Karakoc M, Sarac AJ. The effects of alendronate and calcitonin on cytokines in postmenopausal osteoporosis. A 6-mo